Group 1 - Huiyu Pharmaceutical's subsidiary received drug registration certificate for Carboxymethyl Sodium Injection, which is used for treating bleeding diseases in various medical fields [1] - Baihe Co., Ltd. announced a plan for a director to reduce holdings by up to 424,000 shares, representing 0.6625% of the total share capital [1] - Kingood Co., Ltd. received a notification from a global leading automaker for a wheel project, expected to start mass production in 2026 with a lifecycle of 10 years [1][2] Group 2 - Wanhua Chemical plans to repurchase shares worth between 300 million and 500 million yuan, with a maximum repurchase price of 99.36 yuan per share [2] - Warner Pharmaceutical's subsidiary received approval for Acetylcysteine raw material drug, primarily used for treating respiratory diseases [3] - ST Mingcheng plans to publicly transfer 45% equity of its subsidiary, aiming to optimize asset structure [4] Group 3 - Qixia Construction announced a plan to reduce up to 31.5 million shares, accounting for 3% of total share capital [5][6] - Zhejiang Rongtai intends to invest 20 million yuan to establish a wholly-owned subsidiary focused on intelligent robotics [7] - Yuandong Biological received drug registration for Chloral Hydrate Enema, used for sedation and seizure control in children [9] Group 4 - Jiemai Technology's subsidiary signed a strategic cooperation agreement with a solid-state battery company to produce high-safety composite conductive materials [10] - Xianju Pharmaceutical received drug registration for Progesterone Soft Capsules, used for treating functional disorders due to luteal deficiency [11] - Lanhua Kecai's subsidiary reported a temporary production halt, with the resumption date yet to be determined [13] Group 5 - Sinopharm Modern's subsidiary received drug registration for Tocilizumab Tablets, used for treating rheumatoid arthritis and other conditions [15] - Shanghai Bank announced the resignation of its vice president due to organizational adjustments [17] - Shanghai Pharmaceutical's Ephedrine Injection passed the consistency evaluation for generic drugs [19] Group 6 - Rundu Co., Ltd. received drug registration for Amlodipine and Olmesartan Tablets, aimed at treating hypertension [21] - Zhong'an Technology announced that 61 million shares held by its controlling shareholder will be auctioned [23] - Shanghai Washba plans to purchase patent assets and establish two subsidiaries focused on hydrogen energy and solid-state battery technologies [25] Group 7 - Nuo Cheng Jianhua's new drug Tafasitamab received approval for treating relapsed/refractory diffuse large B-cell lymphoma [26] - Benli Technology plans to use up to 200 million yuan of idle funds for cash management and financial investments [28] - Taiji Co., Ltd. intends to use 60 million yuan of idle funds to purchase financial products [29] Group 8 - Haishi Co. announced that its innovative drug Anreke Fen Injection received drug registration for treating postoperative pain [32] - Yulong Co. will have its stock delisted on May 27, 2025, following a decision by the Shanghai Stock Exchange [36] - Weifu High-Tech plans to establish a joint venture with Shanghai Baolong Automotive Technology [38] Group 9 - Xichang Electric Power expects a net profit reduction of approximately 5.4 million yuan due to adjustments in the time-of-use electricity pricing mechanism [39] - Alter signed a contract worth 6.8 billion yen for the development and procurement of large truck EV kits [41] - Zhonglian Heavy Industry plans to acquire controlling stakes in its financing leasing subsidiary through public bidding [42] Group 10 - Sanyou Medical's executive plans to reduce holdings by up to 1.44% of the company's shares [43] - Hangyang Co. plans to establish a subsidiary for large modular cryogenic equipment manufacturing with an estimated investment of 557 million yuan [44] - FAW Fuwi received a notification for a dashboard project from a well-known new energy brand, with total sales expected to reach 1.06 billion yuan [45]

Group 1 - The legal opinion letter is issued by Allbright Law Offices regarding the cancellation of certain unvested restricted stock granted under Zhejiang Benli Technology Co., Ltd.'s 2024 Restricted Stock Incentive Plan [1][2] - The law firm confirms that the necessary procedures and approvals for the cancellation of the unvested restricted stock have been completed as of the date of the legal opinion [4][6][10] - The company has decided to cancel a total of 96,250 shares of restricted stock that were granted but not vested, due to the departure of two incentive targets and the failure to meet performance targets [8][10] Group 2 - The performance assessment for the first vesting period of the incentive plan was based on revenue and net profit targets, which were not met, resulting in a 0% vesting ratio for the company [8][10] - The company achieved a revenue of 708.83 million yuan and a net profit of 64.57 million yuan in 2024, which did not meet the required performance thresholds for the vesting of the restricted stock [8][10] - The board and the compensation and assessment committee have agreed that the cancellation of the unvested restricted stock complies with relevant laws and regulations, and does not harm the interests of shareholders [10]

Core Viewpoint - Zhejiang Benli Technology Co., Ltd. has announced the cancellation of 962,500 unvested restricted stocks from its 2024 incentive plan due to the departure of two incentive targets and failure to meet performance targets [1][4][7]. Summary by Sections Approval Procedures - The company held multiple board and supervisory meetings to review and approve the incentive plan and its related documents, ensuring compliance with legal and regulatory requirements [2][3][4]. Cancellation Details - The cancellation includes 25,000 shares due to the departure of two incentive targets and 937,500 shares due to the company's failure to meet the performance targets set for the first vesting period [5][7]. Performance Targets - The performance assessment for the first vesting period was based on revenue and net profit targets. The company reported a revenue of 708.83 million yuan and a net profit of 64.57 million yuan for 2024, which did not meet the required thresholds [6][7]. Impact on the Company - The cancellation of the restricted stocks will not materially affect the company's financial status or operational results, nor will it impact the stability of the core team or the continuation of the incentive plan [7][9]. Opinions from Committees - Both the Board's Compensation and Assessment Committee and the Supervisory Committee have agreed that the cancellation process complies with relevant laws and regulations, and does not harm the interests of shareholders [8][9]. Legal Opinion - The legal counsel confirmed that the cancellation of the unvested restricted stocks has followed necessary procedures and obtained required approvals, aligning with applicable laws and the company's regulations [9].

Group 1 - The company held its seventh meeting of the fourth Supervisory Board on May 21, 2025, with all three supervisors present, and the meeting was conducted in accordance with legal and regulatory requirements [1][2]. - The Supervisory Board approved the proposal to use part of the idle raised funds for cash management and entrusted financial management of idle self-owned funds, aiming to enhance fund utilization efficiency and protect shareholder interests [1][2]. - The Supervisory Board also approved the proposal to annul part of the granted but unvested restricted stock from the 2024 incentive plan, confirming that this action complies with relevant laws and regulations and will not adversely affect the company's financial status or shareholder interests [2]. Group 2 - The voting results for both proposals were unanimous, with 3 votes in favor and no votes against or abstaining [2].

作废部分已授予尚未归属的限制性股票相关事项的 法律意见书 地址：上海市浦东新区银城中路 501 号上海中心大厦 11/12 层 电话：021-20511000 传真：021-20511999 邮编：200120 上海市锦天城律师事务所 法律意见书 上海市锦天城律师事务所 关于浙江本立科技股份有限公司 2024 年限制性股票激励计划 上海市锦天城律师事务所 关于浙江本立科技股份有限公司 2024 年限制性股票激励计划 作废部分已授予尚未归属的限制性股票相关事项的 法律意见书 致：浙江本立科技股份有限公司 上海市锦天城律师事务所（以下简称"锦天城"或"本所"）接受浙江本立科技 股份有限公司（以下简称"公司"或"本立科技"）的委托，担任公司"2024 年限制 性股票激励计划"（以下简称"本次激励计划"）的法律顾问，根据《中华人民共和 国公司法》(以下简称"《公司法》")、《中华人民共和国证券法》(以下简称"《证 券法》")、《上市公司股权激励管理办法》(以下简称"《激励管理办法》"或《管 理办法》)、《深圳证券交易所创业板上市公司自律监管指南第1号——业务办理》 （以下简称"《监管指南》"）等有关法律法规的规定，按 ...

证券代码：301065 证券简称：本立科技 公告编号：2025-020 浙江本立科技股份有限公司 第四届监事会第七次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 浙江本立科技股份有限公司（以下简称"公司"）第四届监事会第七 次会议于 2025 年 5 月 21 日在公司三楼会议室以现场的方式召开。本次会 议通知已于 2025 年 5 月 15 日以邮件方式向公司全体监事发出。本次会议 由公司监事会主席钱沛良先生主持，会议应到监事 3 人，实到监事 3 人， 公司部分高级管理人员列席会议。会议的召集、召开和表决程序符合《公 司法》和《公司章程》的有关规定，形成的决议合法有效。 二、监事会会议审议情况 经认真审查，监事会认为：公司本次作废部分已授予但尚未归属的限 制性股票符合有关法律、法规及公司激励计划的相关规定，不会对公司的 财务状况和经营成果产生实质性影响，不存在损害公司股东利益的情况。 因此，监事会同意公司本次作废部分已授予但尚未归属的限制性股票共计 96.25万股。 表决结果：3 票同意，0 票反对，0 票弃权。 三 ...

浙江本立科技股份有限公司 关于作废 2024 年限制性股票激励计划部分已授予 尚未归属的限制性股票的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假 记载、误导性陈述或者重大遗漏。 浙江本立科技股份有限公司（以下简称"公司"）于 2025 年 5 月 21 日召开 第四届董事会第七次会议和第四届监事会第七次会议，审议通过了《关于作废 2024 年限制性股票激励计划部分已授予尚未归属的限制性股票的议案》，根据 《浙江本立科技股份有限公司 2024 年限制性股票激励计划（草案）》（以下简 称"《激励计划》"）的规定及公司 2024 年第二次临时股东大会的授权，公司 董事会同意作废 2024 年限制性股票激励计划（以下简称"本次激励计划"）部 分已授予但尚未归属的限制性股票共 96.25 万股。现将有关事项说明如下： 证券代码：301065 证券简称：本立科技 公告编号：2025-021 一、已履行的相关审批程序 （一）2024年8月28日，公司召开第四届董事会第二次会议，审议通过了《关 于<浙江本立科技股份有限公司2024年限制性股票激励计划（草案）>及其摘要 的议案》《关于<浙江本立科技 ...

二、董事会会议审议情况 经与会董事认真审议，形成以下决议： （一）审议通过了《关于使用部分闲置募集资金进行现金管理和闲置 自有资金进行委托理财的议案》 经认真审查，公司董事会同意公司及全资子公司在不影响公司正常生 产经营和募集资金投资计划正常进行并确保资金安全的情况下，使用不超 过人民币 2 亿元（含本数，下同）的闲置募集资金进行现金管理和不超过 人民币 3 亿元（含等值外币）的闲置自有资金进行委托理财，额度使用期 证券代码：301065 证券简称：本立科技 公告编号：2025-019 浙江本立科技股份有限公司 第四届董事会第七次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 浙江本立科技股份有限公司（以下简称"公司"）第四届董事会第七 次会议于 2025 年 5 月 21 日在公司三楼会议室以现场结合通讯的方式召开。 本次会议通知已于 2025 年 5 月 15 日以邮件方式向公司全体董事发出。本 次会议由公司董事长吴政杰先生主持，会议应到董事 7 人，实到董事 7 人， 公司监事、高级管理人员列席会议。会议的召集、召开 ...

证券代码：301065 证券简称：本立科技 公告编号：2025-022 浙江本立科技股份有限公司 关于使用部分闲置募集资金进行现金管理和闲置自有资金 进行委托理财的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 浙江本立科技股份有限公司（以下简称"公司"）于 2025 年 5 月 21 日召开 的第四届董事会第七次会议和第四届监事会第七次会议审议通过了《关于使用部 分闲置募集资金进行现金管理和闲置自有资金进行委托理财的议案》，同意公司 及全资子公司在不影响公司正常生产经营和募集资金投资计划正常进行并确保 资金安全的情况下，使用不超过人民币 2 亿元（含本数，下同）的闲置募集资金 进行现金管理和不超过人民币 3 亿元（含等值外币，下同）的闲置自有资金进行 委托理财，额度使用期限为自董事会审议通过之日起 12 个月，在上述额度及使 用期限内资金可循环滚动使用，该议案无需提交股东大会审议。现将具体情况公 告如下： 一、募集资金基本情况 经中国证券监督管理委员会以证监许可[2021]2601 号《关于同意浙江本立 科技股份有限公司首次公开发行股票注册的批复》核准 ...

长城证券股份有限公司 关于浙江本立科技股份有限公司 使用部分闲置募集资金进行现金管理和闲置自有资金进行 委托理财事项的核查意见 长城证券股份有限公司（以下简称"长城证券"或"保荐机构"）作为浙江本 立科技股份有限公司（以下简称"本立科技"或"公司"）首次公开发行股票并 在创业板上市之保荐机构，根据《证券发行上市保荐业务管理办法》《上市公司 监管指引第2号—上市公司募集资金管理和使用的监管要求》《深圳证券交易所创 业板股票上市规则》《深圳证券交易所上市公司自律监管指引第2号——创业板上 市公司规范运作》等相关规定，长城证券对本立科技拟使用部分闲置募集资金进 行现金管理和闲置自有资金进行委托理财的事项进行了核查，核查的具体情况如 下： 一、募集资金基本情况 经中国证券监督管理委员会《关于同意浙江本立科技股份有限公司首次公 开发行股票注册的批复》（证监许可[2021]2601号）同意，公司获准向社会公开 发行人民币普通股（A 股）股票17,680,000股，每股面值1元，每股发行价格 为人民币42.50元，募集资金总额为人民币751,400,000.00元，扣除发行费用总 额68,144,762.18元（不含增值税 ...